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FACTORS AFFECTING METFORMIN AND CLOMIPHENE’S REPRODUCTIVE 
EFFICACY IN PCOS WOMEN 
Abstract 
Polycystic Ovarian Syndrome (PCOS) is a heterogeneous multifactorial disorder in which the ovarian 
dysfunction is the main cause of an ovulatory infertility. Metformin and Clomiphene Citrate (CC) are 
two effective drugs to induce ovulation in these patients. The study aimed to ascertain the effect of 
obesity, serum insulin and free testosterone levels on fertility success with metformin and CC as first 
line approaches in PCOS. This clinical study was a retrospective multicenter cohort study conducted in 
nine gynecology and endocrinology clinics. It included (61) PCOS women, aged (18-32) years, having 
desire to conceive, and free from the study medications for more than six months. Patients were divided 
to metformin receiving and CC receiving groups. Main outcomes of measure were; pregnancy rate, and 
improvement in PCOS as detected by ultrasound on their second visit. Results showed that CC was 
more effective in non-obese users (P0.05). Overall improvement was affected by Serum Free Testosterone 
(SFT) in both study groups (P>0.05). Metformin was effective regardless of patient’s SFT levels, while 
CC was effective in patients with high SFT levels. There was a significant association between obesity 
and pregnancy rate in metformin users (P0.05). However, CC was less effective than metformin in overall 
improvement (OR=0.53, P>0.05,) suggesting metformin as the possible drug of choice regardless to 
obesity, serum insulin and SFT levels. 
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1. INTRODUCTION 
Polycystic Ovarian Syndrome (PCOS) is a heterogeneous multifactorial disorder 
characterized by polycystic ovaries, hyperandrogenism and ovulatory dysfunction (Rotterdam 
ESHRE/ASRM group, 2004). Chronic oligoanovulation is one of the pivotal features of the PCOS, 
whose related ovarian dysfunction is the main cause of anovulatory infertility (Hull, 1987; Azziz 
et al, 2004). Several approaches have been proposed to induce ovulation in women with PCOS 
(Palomba et al, 2004). Clomiphene citrate (CC) and metformin are two effective drugs used to 
induce ovulation in those patients (Palomba et al, 2007). Clomiphene citrate was the first agent 
used for ovulation induction’s experiments in oligomenorrheic women. It has been proven 
effective in ovulation induction for women with PCOS and should be considered as the first-line 
of therapy (Saha, Kaur & Saha, 2012). 
Insulin resistance (IR) and secondary hyperinsulinemia affect approximately 65-70% of 
women with PCOS. This could be due to; genes related to insulin resistance in PCOS, family 
history of diabetes mellitus type II, or even obesity (Palomba et al, 2005; Palomba, Pasquali, Orio 
& Nestler, 2009). Many PCOS women are obese (Body Mass Index (BMI) of 30 kg/m² or more) 
(Loret do Mola, 2009), which further exacerbates their IR (Johnson, Bontekoe & Stewart, 2011).  
Metformin likely plays its role in improving ovulation induction in women with PCOS via 
several mechanisms. Metformin reduces insulin levels, thus altering insulin’s effect on ovarian 
androgen biosynthesis and resulting in a reduction of ovarian gluconeogenesis. In addition, 
metformin decreases hyperandrogenism, theca cell proliferation, and endometrial growth (Shaw 
et al, 2005; Nestler & Jakubowicz, 1996).  
It is still unclear whether CC or metformin should be initially administered to induce 
ovulation in PCOS patients. In a meta-analysis done by Palomba et al., the Odds ratio (OR) 
between CC and metformin was 1.22 for pregnancy rate (Palomba et al, 2009). In another study, 
Legro et al. reported that CC alone resulted in significantly greater live birth rates than metformin 
alone, with percentage of 22.5% and 7.2% respectively (Lergo et al, 2007). As long as multiple 
births were only seen with CC therapy, it was suggested by the data of the PPCOS trial that if the 
goal of infertility treatment is to achieve a singleton gestation, CC may not be successful (Barbieri, 
2007). On the other hand, the side effects of metformin are mainly gastrointestinal, although the 
sustained release preparation may have an overall lower rate of side effects (Mathur, Alexander, 
Yano, Trivax & Azziz 2008). 
A number of pre-specified factors were identified in determining the clinical parameters 
that may predict prognosis or chance of success between metformin and CC in PCOS patient 
groups. Body mass index was stated in the UK National Institute of Clinical Excellence (NICE) 
and Society of Obstetricians and Gynecologists of Canada (SOGC) Guidelines to be an important 
factor, with a recommendation that metformin was advisable to be used in PCOS women having 
visceral obesity (Saha et al, 2012). In previous Randomized Controlled Trials (RCTs), obese 
women had a particularly poor response to metformin (Lergo et al, 2007; Zein, Jamaluddine, 
Ibrahim & Norman, 2009), whereas in another trial on non-obese women, they favored metformin 
(Hull, 1987).   
 Hyperinsulinemia is condition which is demonstrated by elevated insulin levels on a 2-hour 
75-g load glucose tolerance test. It is an important parameter used to decide whether or not to 
initiate metformin therapy in women with PCOS. This is because metformin has a better 
predictable response than CC in hyperinsulinemic PCOS women due to its insulin sensitization 
(Barbieri, 2007).  
There exist only a limited number of studies showing the relationship between serum free 
testosterone (SFT) and the response to CC or metformin in PCOS. However, a higher level of 
SFT, as an index for PCOS severity, may predict a better response to clomiphene, as long as CC 
could be more effective for cases intractable to treatment (Johnson et al, 2011). 
Due to the lack of comprehensive documentation about PCOS in Lebanon, this retrospective 
multicenter study was conducted to get more insight on main factors predicting fertility success 
with the commonly prescribed medications, metformin and CC. In addition, the study also 
compared, in clinical settings, the efficacy of these two drugs in PCOS patients having desire to 
conceive. 
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2. METHODOLOGY 
This retrospective multicenter cohort study, approved by the Institutional Review Board of 
Beirut Arab University, was conducted in Lebanon during 2011-2012. Total of one hundred thirty 
five PCOS patients’ medical profiles from nine Gynecology and Endocrinology private outpatient 
clinics were reviewed. Sixty-one out of the 135 profiles had the adequate data to be eligible for 
this study. The included medical profiles for patients were from  2009 – 2011, and were screened 
for the following data; the demographic data (age on presentation, weight, height and BMI), the 
gynecological history (number of pregnancies, number living birth and abortions before 
enrolment), previous use of study medications (since more than 6 months), laboratory tests (such 
as FSH, LH, serum Insulin and free testosterone) and diagnostic procedures (such as ovarian 
ultrasound imaging on presentation and on their second visit at least four months after 
presentation). 
The inclusion criteria in this study included; married patients diagnosed with PCOS 
(regardless of the etiology), patients aged eighteen years and above, patients who have been 
presented for at least one follow up visit, and finally patients who were free from study medications 
in the last six months and did not receive other ovulation induction medications (human chorionic 
gonadotropin). The patients in metformin group received metformin in a range of 500-2550 mg 
orally daily. The CC group patients received 50 mg orally twice daily for five days, starting from 
the fifth day of the menstrual cycle and repeated for maximum of 3 cycles. The exclusion criteria 
in this study included; menopausal patients, pregnant PCOS patients, and all patients having 
androgen excess secondary to any cause other than PCOS related hyperandrogenism or obesity. 
The reproductive outcomes in this study were of concern, including; pregnancy rate (number 
of patients who became pregnant on the second visit (first follow up visit)), and improvement in 
polycystic ovaries (number of non-pregnant patients who had a decrease in the number of ovarian 
cysts on the second visit). These outcomes of measure were based on comparing the ultrasound 
imaging data done for each patient on presentation with the ultrasound done on their first follow 
up visit (at least four months after getting the prescription of metformin or CC on presentation).  
This comparison helped in detecting any improvement in PCOS, taking into consideration the 
factors likely to have a differential influence on the likelihood of success between the two 
medications, such as weight, serum insulin and free testosterone levels.  
Data were statistically analyzed using “Megastat” program for excel (version 8.9). The 
mean, standard deviation (SD), percentage and Odds ratio (OR) were calculated when appropriate. 
The study groups showed normal distribution, thus the parametric Student’s t test was used to 
compare between the study groups. The Chi square test was also used whenever appropriate and 
the results were considered significant at P<0.05, with a Confidence Interval (CI) of 95%. 
 
 
3. RESULTS 
 Both CC and metformin groups presented with comparable age. However, CC users were 
older than metformin users and had more past history of pregnancy, live birth delivery and 
abortion. Most of the CC group were non-obese, having normal serum insulin level, Luteinizing 
hormone/Follicle Stimulating Hormone [LH/FSH] <2, but had high SFT level. On the other hand, 
obesity and hyperinsulinemia were more common in metformin users; they also had LH/FSH 
around 2, and almost normal SFT level (as indicated in Table 1). 
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 Table 1: The Baseline characteristics in the two study groups 
 
Variable CC group (n=22) 
Metformin group 
(n=39) 
OR P value 
Age (year) ---mean(SD) 26.04 (4.97) 23.49 (3.89)  > 0.01 
BMI (Kg/m²) ---mean(SD) 26.6 (4.11) 29.25 (5.037)  > 0.1 
Gynecological History ---no (%)     
Pregnancy 12 (56%) 6 (15%) 6.6 < 0.001 
Live birth 11 (50%) 2 (5%) 18.5 < 0.001 
Abortion 3 (14%) 4 (10%) 1.38 > 0.5 
Lab data ----mean (SD)     
Serum insulin ----µU/ml 7.91 (4.31) 12.13 (4.71) a  < 0.01 
LH/FSH 1.58 (0.379) 1.85 (1.105) b  < 0.01 
SFT ---pg/ml 7.46 (4.67) 2.22 (1.265) c  < 0.001 
Ultrasound imaging showing polycystic 
ovaries ---no(%) 
22 (100%) 39 (100%)   
 
NB: a n=36, b n=32, c n=21. CC= Clomiphene citrate; OR= Odds ratio; BMI= Body mass index; LH/FSH= Luteinizing 
hormone/ Follicle stimulating hormone; SFT= Serum free testosterone.  
 
 Depending on the overall improvement (pregnancy and/ or a decrease in number of ovarian 
cysts) as detected by ultrasound on the second visit, CC was more effective in its non-obese users 
than obese ones (OR=10, P< 0.05) (as shown in Fig 1). Metformin showed efficacy in both obese 
and non-obese users (OR=1.06, P> 0.05), and was more effective than CC in obese category 
(OR=5.83, P< 0.05) (as shown in Fig 2 and Fig 3, respectively).  
   
 Fig.1: Percentage of overall improvement as detected by ultrasound in CC group according  
to obesity and SFT level. 
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Fig.2: Percentage of overall improvement as detected by ultrasound in metformin group according to 
obesity and SFT level. 
 
 
 
 
 
Fig.3: Comparison of the overall improvement percentages as detected by ultrasound 
 between both study groups.   
 
From the basic characteristics of PCOS patients in metformin group, 18 out of 21 patients, 
whose SFT level was available, had SFT <3.6 pg/ml. Interestingly, metformin was effective in 
patients with high and normal SFT levels (100% vs 89%) (as shown in Fig.2) . Clomiphene Citrate 
was more effective in patients with SFT >3.6 pg/ml (as shown in Fig. 1). In patients having high 
SFT there was no significant association in overall improvement between metformin and CC 
(P>0.05) (as shown in Fig. 3). On the other hand, in those having normal SFT, 89% of metformin 
users showed overall improvement, while CC failed to induce improvement in the only two 
patients who used CC and had normal SFT level (as shown in Fig. 2 and Fig. 1, respectively). 
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 In order to get further description of metformin patients’ characteristics and its impact on 
the outcome (taking into consideration the obesity and serum insulin), 36 of metformin patients 
whose serum insulin level was available were divided into obese and non-obese groups. Each of 
these groups was subdivided according to serum insulin level. There was a significant association 
between obesity and pregnancy in those having serum insulin>10µU/ml and those having serum 
insulin<10µU/ml (OR=0.02, P< 0.05, and P<0.05, respectively), in which metformin was more 
effective in inducing pregnancy in non-obese patients. On the other hand, there was no significant 
association between obesity and overall improvement in those having serum insulin>10µU/ml and 
those having serum insulin<10µU/ml (P>0.05) (as indicated in Table 2). 
 
Table 2: Patients' outcome as detected by ultrasound imaging in metformin users  
according to BMI and serum insulin level* 
 
Serum 
Insulin 
BMI Pregnant Improved 
Overall 
improvement 
No improvement 
>10 µU/ml a 
>30 Kg/m2 15 1 10 11 4 
<30 Kg/m2 11 9 2 11 0 
<10 µU/ml b 
>30 Kg/m2 5 0 3 3 2 
<30 Kg/m2 5 4 0 4 1 
 
BMI= Body mass index. *n=36 
a P< 0.05 for the association between obesity and pregnancy (OR=0.02). P>0.05 for the association between obesity 
and overall improvement. 
b P< 0.05 for the association between obesity and pregnancy. P>0.05 for the association between obesity and overall 
improvement. 
 
The comparison of metformin and CC’s outcomes in the study sample showed no difference 
between metformin and CC in inducing pregnancy (OR=0.83, P>0.05). Clomephene Citrate was 
less effective than metformin in overall improvement as detected by ultrasound on the second visit 
(OR= 0.53, P>0.05) (as indicated in Table 3). 
 
Table 3: Outcomes of measure in the two study groups 
 
Variable CC group (n=22) Metformin group (n=39) OR 
P 
val
ue 
Pregnancy ---no(%) 7 (32%) 14 (36%) 0.83 NS 
Overall improvement ---no(%) 14 (64%) 30 (77%) 0.53 NS 
 
       CC= Clomiphene citrate; OR= Odds ratio; NS= non significant. 
 
 
4. DISCUSSION 
In this study (as indicated in Table 1), PCOS patients using CC had more past history of 
pregnancy, live birth delivery and abortion than metformin users due to their older age. Patients 
prescribed CC were almost non-obese, and most of them presented with around normal serum 
insulin levels. Obesity was more prominent in the metformin group, and the patients were mainly 
hyperinsulinemic since obesity is a contributing factor in developing hyperinsulinemia and IR 
(Tsilchorozidou, Overton & Conway, 2004). 
 In CC group, SFT was mainly higher than 3.6 pg/ml. The mean was 7.46pg/ml for SFT and 
1.58 for LH/FSH. This high testosterone level is due to a primary ovarian hyperandrogenism in 
the non-obese PCOS patients (Nelson, Legro, Strauss & McAllister, 1999). On the other hand, 
metformin users had mainly a normal SFT level and a mean LH/FSH of 1.85. The normal SFT 
level can be reflected by the extraglandular aromatization of excessive circulating androgen to 
extraglandular estrone (Kasper et al, 2005, p2204-2205).  
In the review of the impact of obesity on the outcome in both groups, CC was more effective 
in its non-obese users than obese ones (OR= 10, P<0.05) (as shown in Fig.1). On the other hand, 
obesity had a non-significant association with the overall improvement in metformin group 
(P>0.05) (as shown in Fig.2).  
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In non-obese patients, there was no difference in overall improvement in both groups (P> 
0.05) (as shown in Fig. 3). This is compatible with Johnson et al. finding which stated that there 
was no evidence of significant differences in outcomes for those with BMI≤32 kg/m2, whether 
treated with metformin or CC (Johnson et al, 2011). 
This study supports that SFT can be considered as a criterion for selection between the two 
drugs, because most of CC patients had a high SFT level and the drug showed efficacy in the 
overall improvement of this category. Previous trials also support that a higher level of free 
testosterone, as an index for PCOS severity, may better predict the response to CC (Johnson et al, 
2011), which can be due to the improvement in the primary ovarian hyperandrogenism. Moreover, 
most of metformin patients had a normal SFT level. The drug was effective in their overall 
improvement regardless of SFT level because metformin helps in decreasing glucose intolerance, 
hyperinsulinemia, hyperandrogenism and ovulatory dysfunction associated with PCOS (Saha et 
al, 2012; Nestler et al, 1996). However, there was no difference between CC and metformin in 
overall improvement (P>0.05) in PCOS patients having high SFT levels. Also, metformin was 
more effective than CC in patients having normal SFT levels. 
Metformin was effective in obese and non-obese patients regardless of their serum insulin 
level, yet it induced pregnancy in the non-obese patients rather than the obese ones (as indicated 
in Table 2). This is compatible with the insulin sensitization effect of metformin in case of 
hyperinsulinemia, and Johnson et al’s outcome in which women with lower BMI may respond 
better to metformin than obese women (Johnson et al, 2011). In addition, our data proves the 
necessity of metformin’s usage with the lifestyle modification (structural exercise, low glycemic 
index diet, hypocaloric diet, etc..) to improve the outcome in obese patients. This outcome supports 
the SOGC recommendations in that lifestyle modifications should be the first-line option for 
overweight and obese PCOS women because it has been proven effective in achieving pregnancy 
in these women (Saha et al, 2012). 
 There was no significant difference between metformin and CC in this study regarding 
pregnancy induction (P> 0.05, OR=0.83), while metformin was more effective than CC in overall 
improvement as detected by ultrasound on the second visit (P> 0.05, OR of CC/metformin= 0.58) 
(as indicated in Table 3). This was compatible with findings of Palomba et al.’s meta-analysis, in 
which no significant difference was observed in pregnancy rate between CC and metformin (OR= 
1.22, 95% CI: 0.23 to 6.55) (Palomba et al, 2009). On the other hand, a previous prospective 
randomized clinical trial also showed that the pregnancy rate was significantly higher in metformin 
group than CC group (15.1 vs. 7.2%, P <0.001) (Palomba et al, 2005). 
The observations above give rise to important questions in terms of managing infertility in 
PCOS: Do these factors really affect the higher clinical response to either metformin or CC? Can 
metformin really replace CC in clinical practice for all PCOS patients due to its safer 
characteristics as a drug? 
  We consider our work as a highlighting study for the mentioned facts and supporting to 
previous clinical trials. Our sample size is considered reasonable as PCOS has a prevalence of 6-
10% as indexed by country. Further prospective studies on larger population are recommended to 
solve these questions. The conservative number of patients in each group may be considered as a 
limitation to this study because there was a difficulty in finding complete medical profiles 
containing the needed data for the study. This is attributed to incomplete documentation issues in 
the clinics; in addition, due to financial issues in the society, as some of the patients were not able 
to perform all of the laboratory tests.  
 
5. CONCLUSIONS 
A- Serum free testosterone levels, serum insulin levels, and obesity can be considered as factors 
to select between metformin and CC, and as predictors for the overall improvement in PCOS 
patients.  
B- Clomiphene Citrate is preferred for non-obese PCOS patients having high SFT levels.  
C- Metformin was effective in all patient categories (taking into consideration the BMI, serum 
insulin and SFT levels); and can be considered as the drug of choice for all PCOS patient 
categories.  
D- Metformin must be used with lifestyle modification in overweight and obese PCOS patients.  
E- There was no difference between metformin and CC in inducing pregnancy. 
F- Metformin was superior to CC in terms of overall improvement. 
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